Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 15, Number 7—July 2009
Research

Clusters of Multidrug-Resistant Mycobacterium tuberculosis Cases, Europe

Isabelle DevauxComments to Author , Kristin Kremer, Herre Heersma, and Dick van Soolingen
Author affiliations: European Centre for Disease Prevention and Control, Stockholm, Sweden (I. Devaux); National Institute for Public Health and the Environment, Bilthoven, the Netherlands (K. Kremer, H. Heersma, D. Van Soolingen)

Main Article

Table 1

Number of diagnosed MDR TB cases reported in 24 European countries and number and proportion of genotyped MDR TB strains, as reported to the MDR TB surveillance project, by year, January 2003 through June 2007*

Country No. cases reported
 No. genotyped strains reported
2003 2004 2005 2006 and 2007 Total All With data (% total cases)
Belgium† (EU) 9 14 7 1 31 15 15 (48)
Croatia 2 1 2 – 5 5 5 (100)
Cyprus (EU) 2 0 1 – 3 – –
Czech Republic (EU) 15 13 4 6 38 11 5 (13)
Denmark (EU) 0 0 5 – 5 4 4 (80)
Estonia (EU) 96 80 72 – 248 228 228 (92)
Finland (EU) 3 0 2 2 7 7 7 (100)
France (EU) 53 53 46 – 152 63 63 (41)
Germany (EU) – – 101 – 101 17 16 (16)
Ireland (EU) 1 2 3 2 8 3 3 (38)
Israel 18 15 12 – 45 39 39 (87)
Italy (EU) 45 18 17 3 83 25 25 (30)
Latvia (EU) 188 208 160 156 712 – –
Lithuania (EU) – 318 338 – 656 56 56 (9)
Macedonia, FYR 4 1 6 4 15 – –
Netherlands (EU) 17 10 7 – 34 44 34 (100)
Norway (EU) 2 4 3 2 11 7 3 (27)
Poland (EU) – – 1 16 17 – –
Romania (EU) – 25 25 – 50 – –
Slovenia (EU) 1 0 1 1 3 2 2 (67)
Spain (EU) – 28 22 – 50 50 50 (100)
Sweden (EU) 7 7 4 3 21 21 18 (86)
Switzerland 9 9 3 4 25 25 20 (80)
United Kingdom (EU)
 68
 52
 54
 –
 174
50
 –
Total 540 858 896 200 2,494 672 593 (39)

*MDR TB, multidrug-resistant tuberculosis; EU, European Union; –, not available; FYR, Former Yugoslav Republic of Macedonia.
†Includes only cases detected at the start of treatment.

Main Article

References
  1. Aziz  MA, Wright  A, Laszlo  A, DeMuynckA, Porels F, Van Deun A, et al. Epidemiology of antituberculosis drug resistance (the global project on anti-tuberculosis drug resistance surveillance): an updated analysis. Lancet. 2006;368:2142–54. DOIPubMedGoogle Scholar
  2. Zignol  M, Hosseini  MS, Wright  A, Weezenbeek  CL, Nunn  P, Watt  CJ, Global incidence of multidrug-resistant tuberculosis. J Infect Dis. 2006;194:479–85. DOIPubMedGoogle Scholar
  3. World Health Organization. Anti-tuberculosis drug resistance in the world. Fourth global report. WHO/HTM/TB/Geneva; 2008.394.
  4. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: The Organization; 2006 [cited 2009 May 26]. Available from http://whqlibdoc.who.int/publications/2006/9241546956_eng.pdf
  5. Gandhi  NR, Moll  A, Sturm  AW, Pawinski  R, Govender  T, Lalloo  U, Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa.
  6. Shah  NS, Wright  A, Bai  GH, Barrera  L, Boulahbal  F, Martín-Casabona  N, Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis. 2007;13:380–7.PubMedGoogle Scholar
  7. Schwoebel  V, Lambregts-van Weezenbeeck  CS, Moro  ML, Drobniewski  F, Hoffner  SE, Raviglione  MC, Standardisation of antituberculosis drug resistance surveillance in Europe. Recommendations of a World Health Organization (WHO) and International Union against Tuberculosis and Lung Disease (IUATLD) Working Group. Eur Respir J. 2000;16:364–71.PubMedGoogle Scholar
  8. Glynn  JR, Whiteley  J, Bifani  P, Kremer  K, van Soolingen  D. Worldwide occurrence of Beijing/W strains of Mycobacterium tuberculosis: a systematic review. Emerg Infect Dis. 2002;8:843–9.PubMedGoogle Scholar
  9. Murray  M, Nardell  E. Molecular epidemiology of tuberculosis: achievements and challenges to current knowledge. Bull World Health Organ. 2002;80:477–82.PubMedGoogle Scholar
  10. Tracevska  T, Jansone  I, Baumanis  V, Marga  O, Lillebaek  T. Prevalence of Beijing genotype in Latvian multidrug-resistant Mycobacterium tuberculosis isolates. Int J Tuberc Lung Dis. 2003;7:1097–103.PubMedGoogle Scholar
  11. Krüüner  A, Hoffner  SE, Sillastu  H, Danilovits  M, Levina  K, Svenson  SB, Spread of drug-resistant pulmonary tuberculosis in Estonia. J Clin Microbiol. 2001;39:3339–45. DOIPubMedGoogle Scholar
  12. European Concerted Action on New Generation Genetic Markers and Techniques for the Epidemiology and Control of Tuberculosis. Beijing/W genotype Mycobacterium tuberculosis and drug resistance. Emerg Infect Dis. 2006;12:736–43.PubMedGoogle Scholar
  13. EuroTB and the national coordinators for tuberculosis surveillance in the WHO European Region. Surveillance of tuberculosis in Europe. Reports on multi-drug resistant tuberculosis. Institut de Veille Sanitaire, Saint-Maurice 2008; France [cited 2009 May 15]. Available from http://www.eurotb.org/mdr_tb_surveillance/pdf/MDR-TB_report6.pdf
  14. Heersma  HF, Kremer  K, van Embden  JD. Computer analysis of IS6110 RFLP patterns of Mycobacterium tuberculosis. Methods Mol Biol. 1998;101:395–422.PubMedGoogle Scholar
  15. Laszlo  A, Rahman  M, Espinal  M, Raviglione  M. Quality assurance programme for drug susceptibility testing of Mycobacterium tuberculosis in the WHO/IUATLD Supranational Reference Laboratory Network: five rounds of proficiency testing, 1994–1998. Int J Tuberc Lung Dis. 2002;6:748–56.PubMedGoogle Scholar
  16. Laszlo  A, Rahman  M, Raviglione  M, Bustreo  F. Quality assurance programme for drug susceptibility testing of Mycobacterium tuberculosis in the WHO/IUATLD Supranational Laboratory Network: first round of proficiency testing. Int J Tuberc Lung Dis. 1997;1:231–8.PubMedGoogle Scholar
  17. EuroTB and the National Coordinators for Tuberculosis Surveillance in the WHO European Region. Surveillance of tuberculosis in Europe. Report on tuberculosis cases notified in 2006, Institut de Veille Sanitaire, Saint-Maurice, France. 2008 Mar.
  18. van Embden  JD, Cave  MD, Crawford  JT, Dale  JW, Eisenach  KD, Gicquel  B, Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology. J Clin Microbiol. 1993;31:406–9.PubMedGoogle Scholar
  19. Kamerbeek  J, Schouls  L, Kolk  A, van Agtervale  M, van Soolingen  D, Kuijper  S, Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. J Clin Microbiol. 1997;35:907–14.PubMedGoogle Scholar
  20. Supply  P, Lesjean  S, Savine  E, Kremer  K, van Soolingen  D, Locht  C. Automated high-throughput genotyping for study of global epidemiology of Mycobacterium tuberculosis based on mycobacterial interspersed repetitive units. J Clin Microbiol. 2001;39:3563–71. DOIPubMedGoogle Scholar
  21. Kremer  K, Glynn  JR, Lillebaek  T, Niemann  S, Kurepina  NE, Kreiswirth  BN, Definition of the Beijing/W lineage of Mycobacterium tuberculosis on the basis of genetic markers. J Clin Microbiol. 2004;42:4040–9. DOIPubMedGoogle Scholar
  22. Manissero  D, Fernandez de la Hoz  K. Surveillance methods and case definition for extensively drug resistant TB (XDR-TB) and relevance to Europe: summary update. Euro Surveill 2006; 11(11):E061103.1.
  23. Supply  P, Allix  C, Lesjean  S, Cadoso-Oelemann  M, Rusch-Gerdes  S, Willery  E, Proposal for standardization of optimized mycobacterial interspersed repetitive unit-variable-number tandem repeat typing of Mycobacterium tuberculosis. J Clin Microbiol. 2006;44:4498–510. DOIPubMedGoogle Scholar
  24. Lambregts-van Weezenbeek  CS, Sebek  MM, van Gerven  PJ, de Vries  G, Verver  S, Kalisvaart  NA, Tuberculosis contact investigation and DNA fingerprint surveillance in the Netherlands: 6 years’ experience with nationwide cluster feedback and cluster monitoring. Int J Tuberc Lung Dis. 2003;7(Suppl 3):S463–70.PubMedGoogle Scholar

Main Article

Page created: November 08, 2010
Page updated: November 08, 2010
Page reviewed: November 08, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external